Alterity Therapeutics Ltd (ATH)
20mins delayed
Movement
1 Year Return
Alterity Therapeutics Ltd Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $52.08 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
ATH Statistics
28 September
1,114 / 2,238
ASX Size Rank
1yr Return
vs Sector (1yr)
+44.23%
vs ASX 200 (1yr)
+76.89%
$52.08 million
Market Cap
Share Issue
1.09 billion
All Ords (%)
N/A
Short Sold
0%
Current Fundamentals
28 September
N/A
PE Ratio
EPS ($)
-0.011
Earnings Yield
-23.33%
NTA ($)
0.01
N/A
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Alterity Therapeutics Limited (ATH, formerly Prana Biotechnology Limited) is an Australian biotechnology company which focusses to commercialise research into Parkinsonian movement disorders, Alzheimer's disease, Huntington disease and other neurodegenerative disorders.
Former Names
Prana Biotechnology Ltd (PBT), 11/04/2019
Upcoming Calendar
| 25 Feb 2021 | Report (Interim) |
| 30 Aug 2021 | Report (Prelim) |
| 8 Sep 2021 | Report (Prelim) |
| 8 Sep 2021 | Report (Annual) |
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Announcements provided by
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
ATH is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Mr David Sinclair | Non-Executive Director | Apr 2019 |
|
| Mr Geoffrey Paul Kempler | Executive Director, Chief Executive Officer, Executive Chairman | Nov 1997 |
|
| Mr Brian Derek Meltzer | Non-Executive Director | Dec 1999 |
|
| Mr Peter Ashley Marks | Non-Executive Director | Jul 2005 |
|
| Mr Lawrence Gozlan | Non-Executive Director | Aug 2011 |
|
| Mr Tristan Edwards | Non-Executive Director | Apr 2019 |
|
| Kathryn Andrews | Chief Financial Officer | N/A | |
| David Stamler | Chief Medical Officer and Senior Vice President Clinical Development | N/A | |
| Phillip Hains | Company Secretary | N/A |
Director Transactions
ATH directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
| Date | Director | Type | Amount | Price | Value | Notes |
|---|---|---|---|---|---|---|
| 18/09/20 | David Sinclair | Issued | 7,000,000 | $0.054 | $378,000 | Issue of options. |
| 18/09/20 | Geoffrey Kempler | Issued | 14,000,000 | $0.054 | $756,000 | Issue of options. |
| 18/09/20 | Brian Meltzer | Issued | 7,000,000 | $0.054 | $378,000 | Issue of options. |
| 18/09/20 | Peter Marks | Issued | 7,000,000 | $0.054 | $378,000 | Issue of options. |
| 18/09/20 | Lawrence Gozlan | Issued | 7,000,000 | $0.054 | $378,000 | Issue of options. |
| 18/09/20 | Tristan Edwards | Issued | 7,000,000 | $0.054 | $378,000 | Issue of options. |
| 16/11/18 | Ira Shoulson | Issued | 1,250,000 | $0.044 | $55,000 | Issue of options. |
Shareholder Distribution
| Holding Size | 1 - 1,000 | 1,001 - 5,000 | 5,001 - 10,000 | 10,001 - 100,000 | 100,001 and over | Total Shareholders |
|---|---|---|---|---|---|---|
| No. of Shareholders | 510 | 1,401 | 822 | 1,883 | 438 | 5,054 |
Top 20 Shareholders
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 523,867,497 | 48.28% |
| Life Biosciences Llc | 269,905,533 | 24.88% |
| Baywick Proprietary Limited |
14,165,000 | 1.31% |
| J P Morgan Nominees Australia Pty Limited | 8,041,588 | 0.74% |
| Citos Super Pty Ltd |
5,000,000 | 0.46% |
| Donatello Nizzi | 4,678,362 | 0.43% |
| Mr James V Babcock | 3,980,263 | 0.37% |
| Citicorp Nominees Pty Limited | 3,705,746 | 0.34% |
| The Entrust Group Inc |
3,598,740 | 0.33% |
| Fagan Harris Pty Ltd |
3,249,715 | 0.30% |
| Mr Christopher Ferris | 3,000,000 | 0.28% |
| NRB Developments Pty Ltd | 2,970,000 | 0.27% |
| Capuano Nominees Pty Ltd |
2,750,000 | 0.25% |
| One Lucky Oak Pty Ltd |
2,200,342 | 0.20% |
| Rentuk Shore Pty Ltd | 2,128,205 | 0.20% |
| Mr Lukasz Pieprzyk | 2,022,681 | 0.19% |
| Mr Mark Victor Gordon + Miss Linda June Grace Gordon | 2,000,000 | 0.18% |
| Mr Shaun Anthony Neilsen | 2,000,000 | 0.18% |
| Ms Pamela Joy Bates | 2,000,000 | 0.18% |
| Moubray Pty Ltd |
2,000,000 | 0.18% |
| All other shareholders | 20.45 % | |
The Top 20 Shareholders of ATH hold 79.55% of shares on issue.
ATH Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
ATH Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|---|---|
| 2020 | $0.017 | 30 June |
| 2019 | $0.029 | 28 June |
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Commercialise research into Parkinsonian movement disorders, Alzheimer's disease, Huntington disease and other neurodegenerative disorders.
Incorporated: in VIC on 11/11/1997 as Prana Corporation Pty Ltd. Incorporation status changed to "Limited" on 26/11/1999. Name changed to Prana Biotechnology Limited on 05/01/2000.
Level 3, 460 Bourke St
Melbourne VIC 3000
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.